ALLMEDTECH.COM
ALLMEDTECH.COM
MEDICAL, SURGICAL, DENTAL,
PHARMACEUTICALS , OBGYN,
VETERINARY & PET SUPPLIES,
DIAGNOSTIC LAB, COSMETICS,
VACCINES , INJECTABLES , IV ,
GENERIC & OTC MEDICATIONS ,
PHARMACY'S AND MED-SPORT
SUPPLIES & EQUIPMENTS
TOLL FREE: 1-800-939-6944
Prolia
Bone Resorption Inhibitor Denosumab,
Preservative Free 60 mg / mL
Subcutaneous Injection
Prefilled Syringe 1 mL
Amgen 55513071001
Bone Resorption Inhibitor Denosumab,
Preservative Free 60 mg / mL
Subcutaneous Injection
Prefilled Syringe 1 mL
Amgen 55513071001
Product Description
Prolia
Bone Resorption Inhibitor Denosumab,
Preservative Free 60 mg / mL
Subcutaneous Injection
Prefilled Syringe 1 mL
Amgen 55513071001
TERMS & CONDITIONS FOR PURCHASING INJECTABLES & MEDICATIONS : 1- REGULATIONS ON PURCHASE OF INJECTABLES & MEDICATIONS VARY FROM STATE TO STATE . IT IS THE PURCHASER'S RESPONSIBILITY TO KNOW AND COMPLY WITH THE LAWS GOVERNING THE DISTRICT IN WHICH THEY LIVE. 2- INJECTABLES & MEDICATIONS WOULD BE SOLD ONLY TO QUALIFIED CUSTOMERS ( PHYSICIAN OFFICES , DIAGNOSTIC & RESEARCH LABORATORIES , DENTAL OFFICES , HEALTH CARE PROVIDERS , .... ) WITH VALID MEDICAL LICENSE. 3- ORDERS INCLUDING PURCHSE OF INJECTABLES & MEDICATIONS WOULD BE PROCESSED AFTER VERIFICATION OF PURCHASER'S VALID MEDICAL LICENSE TO BE EMAILED AS AN ATTACHMENT TO : ADMIN@ALLMEDTECH.COM OR FAXED TO 323-782-0985 )
Manufacturer # 55513071001 Brand ProliaŽ Manufacturer Amgen Inc Application Bone Resorption Inhibitor Container Type Prefilled Syringe Dosage Form Injection Generic Drug Code 28656 Generic Drug Name Denosumab, Preservative Free NDC Number 55513-0710-01 Storage Requirements Requires Refrigeration Strength 60 mg / mL Type Subcutaneous UNSPSC Code 51182428 User Adults Volume 1 mL Features ProliaŽ (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily Pre-existing hypocalcemia must be corrected prior to initiating ProliaŽ Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2 Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton Protect Prolia from direct light and heat
Bone Resorption Inhibitor Denosumab,
Preservative Free 60 mg / mL
Subcutaneous Injection
Prefilled Syringe 1 mL
Amgen 55513071001
TERMS & CONDITIONS FOR PURCHASING INJECTABLES & MEDICATIONS : 1- REGULATIONS ON PURCHASE OF INJECTABLES & MEDICATIONS VARY FROM STATE TO STATE . IT IS THE PURCHASER'S RESPONSIBILITY TO KNOW AND COMPLY WITH THE LAWS GOVERNING THE DISTRICT IN WHICH THEY LIVE. 2- INJECTABLES & MEDICATIONS WOULD BE SOLD ONLY TO QUALIFIED CUSTOMERS ( PHYSICIAN OFFICES , DIAGNOSTIC & RESEARCH LABORATORIES , DENTAL OFFICES , HEALTH CARE PROVIDERS , .... ) WITH VALID MEDICAL LICENSE. 3- ORDERS INCLUDING PURCHSE OF INJECTABLES & MEDICATIONS WOULD BE PROCESSED AFTER VERIFICATION OF PURCHASER'S VALID MEDICAL LICENSE TO BE EMAILED AS AN ATTACHMENT TO : ADMIN@ALLMEDTECH.COM OR FAXED TO 323-782-0985 )
Manufacturer # 55513071001 Brand ProliaŽ Manufacturer Amgen Inc Application Bone Resorption Inhibitor Container Type Prefilled Syringe Dosage Form Injection Generic Drug Code 28656 Generic Drug Name Denosumab, Preservative Free NDC Number 55513-0710-01 Storage Requirements Requires Refrigeration Strength 60 mg / mL Type Subcutaneous UNSPSC Code 51182428 User Adults Volume 1 mL Features ProliaŽ (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily Pre-existing hypocalcemia must be corrected prior to initiating ProliaŽ Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2 Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton Protect Prolia from direct light and heat